Probiotics are microbes that are claimed to promote health and well-being when added to foods. However, the European Food Safety Authority (EFSA) has so far advised negatively about health claims for probiotics. Companies and scientists have protested against these rejections, sometimes in vigorous language. I argue that EFSA could not have acted differently, given EU regulations and the lack of convincing evidence for some of the claimed effects of probiotics on human health and well-being. One EU regulation that makes it hard to demonstrate the benefits of probiotics is the prohibition of medical claims, i.e. claims that a food prevents or cures a disease. If this prohibition did not exist, manufacturers of nutritional treatments might circumvent the costly procedures required for drugs, and market their products to ill people without thorough proof that they are effective and safe. However, the prohibition is also a legal fiction, because promotion of health and prevention of disease is largely the same thing. EFSA has recently indicated that it will allow health claims based on the ability of probiotics to reduce infections. To a certain extent, this abolishes the distinction between health claims and medical claims. It remains to be seen if probiotics producers can convince EFSA that their products prevent or cure infections and other diseases in humans.
Research-Article
Why the European Food Safety Authority was right to reject health claims for probiotics
M.B. Katan Related information
1 Department of Health Sciences, VU University Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, the Netherlands
Beneficial Microbes: 3
(2)- Pages: 85 - 89

Published Online: June 07, 2012
Abstract
Keywords: health claims, immune response, EU regulation, gut, probiotics, disease, infection
Beneficial Microbes is now a transformative journal
Read more and submit your paper...
Institutional Offers
For institutional orders, please contact sales@wageningenacademic.com.
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
E. Arvidsson Nordström, C. Teixeira, C. Montelius, B. Jeppsson and N. Larsson
-
A.A. Hibberd, C.C. Yde, M.L. Ziegler, A.H. Honoré, M.T. Saarinen, S. Lahtinen, B. Stahl, H.M. Jensen and L.K. Stenman
-
M. Takada, K. Nishida, Y. Gondo, H. Kikuchi-Hayakawa, H. Ishikawa, K. Suda, M. Kawai, R. Hoshi, Y. Kuwano, K. Miyazaki and K. Rokutan
-
K. Chen, G. Zhang, H. Xie, L. You, H. Li, Y. Zhang, C. Du, S. Xu, C. Melsaether and S. Yuan
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
K. Lippert, L. Kedenko, L. Antonielli, I. Kedenko, C. Gemeier, M. Leitner, A. Kautzky-Willer, B. Paulweber and E. Hackl
-
K. Tsilingiri and M. Rescigno
-
T. Wang, X. Hu, S. Liang, W. Li, X. Wu, L. Wang and F. Jin
-
G.J.M. Christensen and H. Brüggemann